MAPT and Alzheimer disease: Higher levels of p-tau and t-tau and lower levels of Aβ1–42 can be detected in the cerebrospinal fluid (CSF) in patients with Alzheimer’s disease (AD) than in patients with FTD, but p-tau, t-tau, and Aβ1–42 are still not suitable as sensitive diagnostic markers [9, 10].